Cases & Deals

  • Home
  • Practices
  • Innate Pharma S.A. receives up to $7.9 million investment from The Institute for Follicular Lymphoma Innovation

Share

Innate Pharma S.A. receives up to $7.9 million investment from The Institute for Follicular Lymphoma Innovation

December 2024

Client(s) Innate Pharma S.A.

Jones Day advised Innate Pharma S.A. in connection with an up to $7.9 million investment from The Institute for Follicular Lymphoma Innovation (IFLI).

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.